Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition
On March12, 2018, we announced our financial results for the quarter and year ended December31, 2017.The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.
Item 2.02 Regulation FD Disclosure
From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. A copy of this slide presentation, dated March2018, is furnished as Exhibit99.2 to this Current Report on Form8-K.
* * *
The information responsive to Items 2.02 and7.01 of this Form8-K and Exhibits 99.1 and 99.2 hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.02 Financial Statements and Exhibits.
Syros Pharmaceuticals, Inc. ExhibitEX-99.1 2 a18-8194_1ex99d1.htm EX-99.1 Exhibit 99.1 Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones Announced Global Collaboration with Incyte to Use Propriety Gene Control Platform to Identify Novel Therapeutic Targets in Myeloproliferative Neoplasms Announced Closing of $46 Million Public Offering of Common Stock,…To view the full exhibit click here
About Syros Pharmaceuticals,Inc. (NASDAQ:SYRS)
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.